Detailed Information
Cited 2 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
- Authors
- Gettinger, SN[Gettinger, Scott N.]; Huber, RM[Huber, Rudolf M.]; Kim, DW[Kim, Dong-Wan]; Bazhenova, L[Bazhenova, Lyudmila]; Hansen, KH[Hansen, Karin Holmskov]; Tiseo, M[Tiseo, Marcello]; Langer, CJ[Langer, Corey J.]; Paz-Ares, LG[Paz-Ares, Luis G.]; West, H[West, Howard]; Reckamp, KL[Reckamp, Karen L.]; Weiss, GJ[Weiss, Glen J.]; Smit, EF[Smit, Egbert F.]; Hochmair, M[Hochmair, Maximilian]; Kim, SW[Kim, Sang-We]; Ahn, MJ[Ahn, Myung-Ju]; Kim, ES[Kim, Edward S.]; Groen, HJM[Groen, Harry J. M.]; Pye, J[Pye, Joanna]; Vranceanu, F[Vranceanu, Florin]; Camidge, DR[Camidge, D. Ross]
- Issue Date
- 20-May-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.